3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
3
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Follicular
10
Lymphoma
9
Lymphoma, Mantle-Cell
8
Lymphoma, Large B-Cell, Diffuse
6
Lymphoma, B-Cell, Marginal Zone
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Lymphoma, B-Cell
4
Lymphoma, Non-Hodgkin
3
Waldenstrom Macroglobulinemia
2
Recurrence
2
Lymphoma, T-Cell, Peripheral
2
Hodgkin Disease
2
Proteostasis Deficiencies
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Lymphoma, T-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Immunoglobulin Light-chain Amyloidosis
1
Immunoblastic Lymphadenopathy
1
Hematopoietic and Lymphoid System Neoplasm
1
Hematologic Neoplasms
1
Fallopian Tube Neoplasms
1
Central Nervous System Neoplasms
1
Advanced Solid Tumor
1
Interventions
Cyclophosphamide
2
sodium-iodide symporter
1
ruxolitinib
1
glofitamab
1
fludarabine
1
duvelisib
1
cemiplimab
1
belinostat
1
X-Rays
1
Specimen Handling
1
Positron-Emission Tomography
1
Photons
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
MAC-ST-001
1
Ipilimumab
1
Immunoglobulin G
1
Gemcitabine
1
Fenretinide
1
Disulfides
1
CTLA-4 Antigen
1
Biopsy
1
Bendamustine Hydrochloride
1
10-propargyl-10-deazaaminopterin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Immunoblastic Lymphadenopathy
×
Bendamustine Hydrochloride
×
Clear all
NCT06522737
2026-04-06
TERZO
SecuraBio
Phase 3
Recruiting
124 enrolled